merged_alzheimers-treatment-kisunla-donanemab.txt
<other>Reasoning based solely on the article provided.</other>
<question_number>1</question_number>
<answer>Risks outweigh slight benefit and decline may not be noticeable</answer>
<question_number>2</question_number>
<answer>Might discourage patients from participating in other clinical trials and slow progress</answer>
<question_number>3</question_number>
<answer>No correlation</answer>
<question_number>4</question_number>
<answer>Could negatively affect perception of safety</answer>
<question_number>5</question_number>
<answer>Patients can stop treatment after amyloid clearance</answer>
<question_number>6</question_number>
<answer>Might discourage patients from participating in other clinical trials</answer>
<question_number>7</question_number>
<answer>Patients can discontinue treatment after amyloid clearance</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Tau levels</answer>